Bio-Rad Laboratories, Inc. (BIO)

Market Cap	8.40B
Revenue (ttm)	2.56B
Net Income (ttm)	-675.90M
Shares Out	26.97M
EPS (ttm)	-24.56
PE Ratio	n/a
Forward PE	29.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,037
Open	317.04
Previous Close	319.55
Day's Range	308.36 - 319.85
52-Week Range	211.43 - 387.99
Beta	1.19
Analysts	Strong Buy
Price Target	358.50 (+15.15%)
Earnings Date	Oct 29, 2025

About BIO

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science e...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1952
• Employees: 7,700
• Stock Exchange: NYSE
• Ticker Symbol: BIO
• Website: https://www.bio-rad.com

Financial Performance

In 2024, Bio-Rad Laboratories's revenue was $2.57 billion, a decrease of -3.92% compared to the previous year's $2.67 billion. Losses were -$1.84 billion, 189.4% more than in 2023.

Analyst Summary

According to 4 analysts, the average rating for BIO stock is "Strong Buy." The 12-month stock price target is $358.5, which is an increase of 15.15% from the latest price.

Price Target

$358.5

(15.15% upside)

Analyst Consensus: Strong Buy